Clinical Trials Logo

Mastocytosis clinical trials

View clinical trials related to Mastocytosis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06210698 Not yet recruiting - Urticaria Clinical Trials

Angioedema Biomarker Research Study

Start date: January 15, 2024
Phase:
Study type: Observational

This clinical trial aims to evaluate and compare novel and commercially available diagnostic assays through blood tests for the differential diagnosis and comprehensive assessment of patients experiencing recurrent angioedema attacks, including both urticarial and non-urticarial angioedema. The primary objective is to assess the efficiency of novel diagnostic assays, both individually and in combination, in comparison to currently available commercial tests. The ultimate goal is to establish the feasibility of developing an affordable and accurate laboratory test capable of diagnosing the diverse etiological manifestations of angioedema.

NCT ID: NCT06065007 Not yet recruiting - Clinical trials for Mastocytosis, Systemic

Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis

Start date: October 15, 2023
Phase:
Study type: Observational

Systemic Mastocytosis is a rare and complex disease caused by accumulation of mast cells. The skin, bones, gastrointestinal tract, bone marrow and liver are the organs most often affected. Symptoms can vary greatly between patients. The study aims to describe the Swedish cohort's self-rated quality of life and levels of disease-related symptoms.

NCT ID: NCT05084872 Not yet recruiting - Mastocytosis Clinical Trials

Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients

HCQMa
Start date: October 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The treatment of systemic mastocytosis has two main axes: - Control of mast cell activation symptoms and - The control of proliferation (accumulation) of mast cells. There is no standard treatment and no treatment has a marketing authorization for the treatment of monoclonal indolent mastocytosis.

NCT ID: NCT00979160 Not yet recruiting - Clinical trials for Systemic Mastocytosis

Evaluation of Response of Dasatinib to Treat Mastocytosis

Start date: November 2009
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, single arm phase II non-randomized study of dasatinib in which subjects with systemic mastocytosis (SM) will be treated with a continuous regimen of dasatinib. Upon completion of a treatment induction period, subjects will be treated with dasatinib at a dose of 100 mg per os (OS) once daily (QD).